Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 6/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13121367 | 0.92 | GSK3B (0.48) | GSK3BLMNACDK2POLBTP53 | |
| SCHEMBL13289489 | 0.89 | GSK3B (0.39) | GSK3BLMNACDK2POLBTP53 | |
| SCHEMBL13289124 | 0.87 | GSK3B (0.40) | GSK3BLMNACDK2POLBTP53 | |
| SCHEMBL13289396 | 0.86 | GSK3B (0.43) | GSK3BCDK2KDM4EMAPTMAPK1 | |
| SCHEMBL13289137 | 0.85 | GSK3B (0.41) | GSK3BLMNACDK2KDM4EMAPT | |
| SCHEMBL13289153 | 0.84 | GSK3B (0.45) | GSK3BCDK2KDM4EMAPTMAPK1 | |
| SCHEMBL13289578 | 0.84 | CDK2 (0.43) | GSK3BCDK2TP53KDM4EMAPT | |
| SCHEMBL13289448 | 0.84 | KDM4E (0.41) | GSK3BLMNACDK2TP53KDM4E | |
| SCHEMBL13289355 | 0.83 | GSK3B (0.43) | GSK3BCDK2KDM4EMAPTMAPK1 | |
| SCHEMBL13289412 | 0.82 | GSK3B (0.47) | GSK3BLMNACDK2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |